Long-term safety and effectiveness of sirolimus for treating LAM

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The MIDAS study is an observational registry that aims to follow patients with lymphangioleiomyomatosis (LAM) who are currently on or considering treatment with mTOR inhibitors like sirolimus or everolimus. The study will enroll 600 participants to monitor lung function and adverse events over a minimum of two years. This research builds on previous findings that indicated sirolimus can stabilize lung function decline but may require ongoing treatment. The decision to initiate therapy will be made collaboratively between the clinician and the patient.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female or male, age 18 or over
* Diagnosis of LAM based on ATS/JRS criteria
* Signed and dated informed consent
* On chronic therapy, newly treated or may be considered for therapy with mTOR inhibitors or previously intolerant of or having failed mTOR inhibitor therapy

Exclusion Criteria:

* Inability to attend at least one RLD Clinic visit per year
* Inability to give informed consent
* Inability or unwillingness to perform pulmonary function testing

Where it's running

• Stanford University Medical Center
  Stanford, California, United States Recruiting
• National Jewish Health
  Denver, Colorado, United States Recruiting
• Mayo Clinic Jacksonville
  Jacksonville, Florida, United States Recruiting
• Emory University School of Medicine
  Atlanta, Georgia, United States Recruiting
• Brigham and Women's Hospital
  Boston, Massachusetts, United States Recruiting
• University of Michigan
  Ann Arbor, Michigan, United States Recruiting

Study contacts

• Study coordinator: Susan McMahan Sellers, BSN, RN
• Email: susan.mcmahan@uc.edu
• Phone: (513) 558-4376

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term safety of Imatinib for patients with Lymphangioleiomyomatosis

  This study is testing if the cancer drug Imatinib is safe and can help women with Lymphangioleiomyomatosis by seeing how it affects their lung health over time.

  Recruiting at 2 sites Phase 1 Columbia University · New York, New York and 1 other locations · NCT06889168

• Registry for pregnant women with Tuberous Sclerosis Complex and Lymphangioleiomyomatosis

  This study is collecting information from pregnant women with Tuberous Sclerosis Complex and Lymphangioleiomyomatosis to see how their health and their babies' health are affected during pregnancy.

  Recruiting Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT06160310

• Collection of biosamples and clinical data for tuberous sclerosis and lymphangioleiomyomatosis

  This study is collecting blood and tissue samples from people with tuberous sclerosis and lymphangioleiomyomatosis to help researchers learn more about these conditions and how they affect the body over time.

  Recruiting at 25 sites National Tuberous Sclerosis Association · Birmingham, Alabama and 25 other locations · NCT05676099

• Comparing nebulized and inhaled albuterol for lung function in women with LAM

  This study is testing whether using a nebulizer or an inhaler for albuterol helps women with LAM breathe better.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT01799538

• Registry for lymphangioleiomyomatosis cases in France

  This study is gathering information about people with lymphangioleiomyomatosis in France to better understand how the disease affects them and how it is being treated.

  Recruiting Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires · Lyon · NCT01484236

• Understanding the disease process of lymphangioleiomyomatosis

  This study looks at how lymphangioleiomyomatosis affects the lungs in women and tries to find out what causes the disease to help develop better treatments.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT00001465

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.